Paraneoplastic neurological syndromes and the role of PET imaging

Oncology

Volumn 78, Issue 2, 2010, Pages 150-156

  Sioka, Chrissa ^a   Fotopoulos, Andreas ^a   Kyritsis, Athanassios P ^b,c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b Department of Neurology ^*  (United States)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cerebellar degeneration; Limbic encephalitis; Paraneoplastic antibody; Paraneoplastic neurological syndrome

Indexed keywords

HU ANTIBODY; HU ANTIGEN;

CEREBELLUM DEGENERATION; DIFFERENTIAL DIAGNOSIS; HUMAN; LUNG SMALL CELL CANCER; PARANEOPLASTIC NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PURKINJE CELL; REVIEW; SENSORY NEUROPATHY; TREATMENT RESPONSE; TUMOR VOLUME;

BREAST NEOPLASMS; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOTHERAPY; LAMBERT-EATON MYASTHENIC SYNDROME; MAGNETIC RESONANCE IMAGING; OVARIAN NEOPLASMS; PARANEOPLASTIC SYNDROMES; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SEIZURES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77950601456     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000312657     Document Type: Review

References (65)

1. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, Honnorat J, Sillevis Smitt PA, Verschuuren JJ, Voltz R: Management of paraneoplastic neurological syndromes: report of an EFNS Task Force. Eur J Neurol 2006; 13: 682-690. (Pubitemid 44139368)
2. McKeon A, Ahlskog JE, Britton JA, Lennon VA, Pittock SJ: Reversible extralimbic paraneoplastic encephalopathies with large abnormalities on magnetic resonance images. Arch Neurol 2009; 66: 268-271.
3. Schilstra A, van Tuijl JH, van Suylen RJ, Faber CG, ten Velde GP: Unclassified rhabdomyosarcoma in a patient with anti-Hu syndrome. Acta Clin Belg 2005; 60: 248-251.
4. Dalmau J, Graus F, Rosenblum MK, Posner JB: Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 1992; 71: 59-72.
5. Lucchinetti CF, Kimmel DW, Lennon VA : Paraneoplastic and oncologic profiles of patients seropositive for type 1 anti-neuronal nuclear autoantibodies. Neurolog y 1998; 50: 652-657.
6. Alamowitch S, Graus F, Uchuya M, Rene R, Bescansa E, Delattre JY: Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120: 923-928.
7. Kraker J: Treatment of anti-Ma2/TA paraneoplastic syndrome. Curr Treat Options Neurol 2009; 11 : 46-51.
8. Almeras C, Soussi N, Molko N, Azoulay-Cayla A, Richard F, Chartier-Kastler EJ: Paraneoplastic limbic encephalitis, a complication of the testicular cancer. Urology 2001; 58: 105.
9. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR: Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-1844.
10. Mathew RM, Vandenberghe R, Garcia-Merino A, Yamamoto T, Landolfi JC, Rosenfeld MR, Rossi JE, Thiessen B, Dropcho EJ, Dalmau J: Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. Neurology 2007; 68: 900-905.
11. Launay M, Bozzolo E, Venissac N, Delmont E, Fredenrich A, Thomas P: Paraneoplastic limbic encephalitis with positive anti-Ri antibodies and mediastinal seminoma (in French). Rev Neurol (Paris) 2008; 164: 612-619.
12. Younes-Mhenni S, Janier MF, Cinotti L, Antoine JC, Tronc F, Cottin V, Ternamian PJ, Trouillas P, Honnorat J: FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004; 127: 2331-2338.
13. Dorn C, Knobloch C, Kupka M, Morakkabati-Spitz N, Schmolling J: Paraneoplastic neurological syndrome: patient with anti-Yo antibody and breast cancer. A case report. Arch Gynecol Obstet 2003; 269: 62-65.
14. Noorani A, Sadiq Z, Minakaran N, Coleman C, Thomas VA, Mokbel K: Paraneoplastic cerebellar degeneration as a presentation of breast cancer-a case report and review of the literature. Int Semin Surg Oncol 2008; 5: 8.
15. Vernino S, Lennon VA: New Purkinje cell antibody (PCA-2) : marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000; 47: 297-305.
16. Henry C, Husson H, de Broucker T: Autoimmune limbic encephalitis with anti-NMDA receptor antibodies and ovarian teratoma: a treatable form of paraneoplastic limbic encephalitis (in French). Rev Neurol (Paris) 2009; 165 : 70-75.
17. Iizuka T, Sakai F: Anti-NMDA receptor encephalitis-clinical manifestations and pathophysiology (in Japanese). Brain Nerve 2008; 60: 1047-1060.
18. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, Dalmau J: Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumorremova l. Neurology 20 08; 70: 504-511.
19. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, Kim KK, Kilimann MW, Lennon VA: Amphiphysin autoimmunity: Paraneoplastic accompaniments. Ann Neurol 2005; 58: 96-107.
20. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F: Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain 2008; 131: 2553-2563.
21. Bernal F, Shams'ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, Honnorat J, Sillevis Smitt P, Graus F: Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin's disease. Neurology 2003; 60: 230-234. (Pubitemid 36152014)
22. Geromin A, Candoni A, Marcon G, Ferrari S, Sperotto A, De Luca S, Fanin R: Paraneoplastic cerebellar degeneration associated with anti-neuronal anti-Trantibodies in a patient with Hodgkin's disease. Leuk Lymphoma 2006; 47: 1960-1963.
23. Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, Marin C, Vecht CJ, Arbizu T, Targa C, Moll JW: Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. J Neuroimmu nol 1997; 74 : 55-61.
24. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, Chapuis F, Aguera M, Decullier E, Duchemin AM, Graus F, Antoine JC: Onconeural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry 2009; 80: 412-416.
25. Buckley C, Oger J, Clover L, Tuzun E, Carpenter K, Jackson M, Vincent A: Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann Neurol 2001; 50: 73-78.
26. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, Clover L, Parkinson A, Bien CG, Omer S, Lang B, Rossor M N, Pa lace J: Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-712.
27. Lopez J, Blanco Y, Graus F, Saiz A: Clinical and immunological profile of limbic encephalitis associated with voltage-gated potassium channel antibodies (in Spanish). Med Clin (Barc) 2009; 133: 224-228.
28. Ohshita T, Kawakami H, Maruyama H, Kohriyama T, Arimura K, Matsumoto M: Voltage-gated potassium channel antibodies associated limbic encephalitis in a patient with invasive thymoma. J Neurol Sci 2006; 250: 167-169.
29. De Vries EF, Dierckx RA, Klein HC: Nuclear imaging of inflammation in neurologic and psychiatric disorders. Curr Clin Pharmacol 2006; 1: 229-242.
30. Dadparvar S, Anderson GS, Bhargava P, Guan L, Reich P, Alavi A, Zhuang H: Paraneoplastic encephalitis associated with cystic teratoma is detected by fluorodeoxyglucose positron emission tomography with negative magnetic resonance image findings. Clin Nucl Med 2003; 28: 893-896.
31. Dreessen J, Jeanjean AP, Sindic CJ: Paraneoplastic limbic encephalitis: diagnostic relevance of CSF analysis and total body PET scanning. Acta Neurol Belg 2004; 104: 57-63.
32. Frings M, Antoch G, Knorn P, Freudenberg L, Bier U, Timmann D, Maschke M: Strategies in detection of the primary tumour in anti-Yo-associated paraneoplastic cerebellar degeneration. J Neurol 2005; 252: 197-201.
33. Leyhe T, Schule R, Schwarzler F, Gasser T, Haarmeier T: Second primary tumor in anti-Ma1/2-positive paraneoplastic limbic encephalitis. J Neurooncol 2006; 78: 49-51.
34. Nagayama S, Koike F, Sakai T, Antoku Y, Yukitake M, Kuroda Y: Case of anti P/Q type VGCC antibody-positive small lung cell carcinoma that occurred with subacute cerebellar degeneration, Lambert-Eaton myasthenic syndrome, and brainstem encephalitis (in Japa nese). Brain Nerve 2008; 60: 1470-1474.
35. 18 F-FDG PET. Clin Nucl Med 2005; 30: 70 4-706.
36. Fakhoury T, Abou-Khalil B, Kessler RM: Limbic encephalitis and hyperactive foci on PET scan. Seizure 1999; 8: 427-431.
37. 18 F-DG-PET scan: a case repor t. Eur Neurol 2001; 45: 18 7-18 9.
38. Troester F, Weske G, Schlaudraff E, Passlick B, Kraemer K: Image of the month. FDG-PET in paraneoplastic limbic encephalitis. Eur J Nucl Med Mol Imaging 2009; 36: 539.
39. 18 F-DG-PET and 3D MRI. J Neuroimaging 2001; 11 : 55-59.
40. Provenzale JM, Barboriak DP, Coleman RE: Limbic encephalitis: comparison of FDG PET and MR imaging findings. AJR Am J Roentgenol 1998; 170: 1659-1660.
41. 18F-f luoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) hyperactivity and 3D magnetic resonance imaging hyperintense lesions in limbic encephalitis. J Neuroimag ing 2002; 12: 283.
42. Basu S, Alavi A: Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 2008; 10: 131-137.
43. Choi KD, Kim JS, Park SH, Kim YK, Kim SE, Smitt PS: Cerebellar hypermetabolism in paraneoplastic cerebellar degeneration. J Neurol Neurosurg Psychiatry 2006; 77: 525-528.
44. 18F-f luoro-2-deoxy-D-glucose positron emission tomography and magnetic resonance imaging of paraneoplastic limbic encephalitis. Arch Neurol 2004; 61: 1785-1789.
45. Gaillard N, Charif M, Carlander B, Pujol JL, Touchon J: Chemotherapy treatment for anti-Hu paraneoplastic syndrome without active malignancy (in French). Rev Neurol (Paris) 2006; 162: 862-865.
46. Voltz R: Neuropsychological symptoms in paraneoplastic disorders. J Neurol 2007; 254 (suppl 2) : II84-II86.
47. 18F]f luoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders. Bra in 2001; 124: 2223-2231.
48. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR: Occult mal igna ncy i n pat ients with susp ected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008; 83: 917-922.
49. Hadjivassiliou M, Alder SJ, Van Beek EJ, Hanney MB, Lorenz E, Rao DG, Sharrack B, Tindale WB: PET scan in clinically suspected paraneoplastic neurological syndromes: a 6-year prospective study in a regional neuroscience unit. Acta Neurol Scand 2009; 119: 186-193.
50. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ: Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008; 26: 4276-4281.
51. Linke R, Schroeder M, Helmberger T, Voltz R: Antibody-positive paraneoplastic neurologic syndromes: value of CT and PET for tumor diagnosis. Neurolog y 2004; 63: 282-286.
52. Chua S, Gnanasegaran G, Cook GJ: Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors) : role of SPECT and PET in imaging bone metastases. Semin Nucl Med 2009; 39: 416-430.
53. 68 Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun 2009; 30: 281-286.
54. 68 Ga-DOTA-NOC PET. Biomed Pharmacother 2008; 62: 667-671.
55. Bading JR, Shields AF: Imaging of cell proliferation: status and prospects. J Nucl Med 2008; 49 (suppl 2) : 64S-80S.
56. 18F]fluorothymidine. Methods 2009; 48: 205-215.
57. 18M F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004; 31: 1659-1672.
58. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Nakajima T, Endo K, Mori M: Fluorine-18ã-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res 2007; 13: 6369-6378.
59. 11 C-methionine PET for evaluation of treatment response of lung cancer after stereotactic radiotherapy. Ann Nucl Med 2004; 18: 669-674.
60. 3 integrin expression. J Nucl Med 2006; 47: 1172-1180.
61. 3 expression in man. Clin Cancer Res 2006; 12: 3942-3949.
62. 18 F-FDG J Nucl Med 2008; 49: 22-29.
63. Linke R, Voltz R: FDG-PET in paraneoplastic syndromes. Recent Results Cancer Res 2008; 170: 203-211.
64. Heiss WD, Pawlik G, Holthoff V, Kessler J, Szelies B: Pet correlates of normal and impaired memory functions. Cerebrovasc Brain Metab Rev 1992; 4: 1-27.
65. 11 C] (R)-PK11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion. Brain 2001; 124: 2014-2027.